P5.24 Immune-mediated Necrotizing Myopathy Associated with Statins: Presentation of two cases and review of the literature

Rugiero, Marcelo; Bettini, Mariela; Bisonni, Ana; Christiansen, Stefan; Cristiano, Edgardo

doi:10.1016/j.nmd.2011.06.1053

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient had been taking statins for at least 12 years (pravastatin, then rosuvastatin). This report, unfortunately not supported by the test for anti-HMGCR antibodies, has many similarities with the limited number of international case series [19][20][21][22][23][24][25][26][27][28][29][30][31] and with individual case reports described both before [32][33][34][35][36][37][38][39][40] and after the use of anti-HMGCR .…”

Section: Srmsupporting

confidence: 53%

Statins and Immune-Mediated Necrotizing Myopathy

Turrin¹

2019

CMI

View full text Add to dashboard Cite

Statins are a well-recognized cause of a variety of skeletal myopathic effects, which generally resolve when discontinuing the treatment. Among autoimmune manifestations associated with statins, there is immune-mediated necrotizing myopathy (IMNM).The present article summarizes the main features of statin-related IMNM, describing diagnosis, classification, epidemiology, treatment, and the main autoantibodies detected.Statins are a well-recognized cause of a variety of skeletal myopathic effects, which generally resolve when discontinuing the treatment. Among autoimmune manifestations associated with statins, there is immune-mediated necrotizing myopathy (IMNM).The present article summarizes the main features of statin-related IMNM, describing diagnosis, classification, epidemiology, treatment, and the main autoantibodies detected.Although it is impossible to define the precise number, it evident that more than 550 statin-related IMNM cases have been described in the literature. Among IMNM, two forms must be distinguished: with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) and with anti-signal recognition particle (SRP) antibodies. The differential diagnosis should be made between the IMNM and self-limited statin-related myopathy, drug-induced rhabdomyolysis, and nonautoimmune myopathies.Patients who have failed to normalize high creatine phosphokinase (CPK) after statin withdrawal should be tested for anti-HMGCR antibodies and, if these are positive, undergo muscle biopsy to confirm the diagnosis of IMNM. Pharmacological therapy of IMNM, not yet based on evidence, involves the use of high-dose corticosteroids, immunosuppressant drugs used alone or in combination, intravenous immunoglobulins (IVIg) or plasmapheresis.

show abstract

Section: Srmsupporting

confidence: 53%

Statins and Immune-Mediated Necrotizing Myopathy

Turrin¹

2019

CMI

View full text Add to dashboard Cite

show abstract

P5.24 Immune-mediated Necrotizing Myopathy Associated with Statins: Presentation of two cases and review of the literature

Cited by 1 publication

References 0 publications

Statins and Immune-Mediated Necrotizing Myopathy

Statins and Immune-Mediated Necrotizing Myopathy

Contact Info

Product

Resources

About